查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446523

美国动物用药品市场规模、份额和趋势分析报告：2024-2030年按产品类型、动物类型、给药途径、分销管道和细分市场预测

U.S. Veterinary Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals), By Animal Type, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10个工作天内

价格

美国动物用药品市场成长及趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国动物用药品市场规模预计将达到218亿美元，2024年至2030年复合年增长率预计为6.8%。

人畜共通感染疾病盛行率上升、牲畜数量增加、对预防性医疗保健的日益关注、宠物医学的进步以及宠物拥有量的增加是推动市场成长的关键因素。根据美国宠物产品协会（APPA）2023年3月发布的报告，狗是美国最受欢迎的宠物，有6,510万个家庭养狗。猫排名第二，有 4,650 万户，淡水鱼排名第三，有 1,110 万户。

由于牲畜数量的显着增加，通用和感染疾病呈上升趋势。这导致人们更加重视预防性医疗措施，以维持牲畜健康和生产力。此外，技术进步透过增强诊断能力、治疗选择和医疗设备，提高动物照护质量，正在彻底改变兽医学。

美国动物用药品市场报告亮点

  • 按产品划分，由于研发投资增加以及医疗产业的进步，製药业在 2023 年以 67.6% 的最大收益占有率引领市场。
  • 按动物类型划分，由于人口增长和畜牧业全球化对动物蛋白的需求不断增加，生产动物细分市场在 2023 年占据最大收益占有率，达到 58.5%。预计伴同性动物在预测期内将表现出最快的复合年增长率。
  • 从给药途径来看，注射剂预计将在2023 年占据市场主导地位，而由于宠物拥有量的增加和对预防性医疗保健的关注，预计口服製剂在预测期内将以显着的复合年增长率增长。
  • 按分销管道划分，预计到 2023 年，兽医院和诊所将占据大部分市场占有率，而电子商务领域预计将在预测期内以最快的复合年增长率增长。
  • 2024年2月，默克宣布签署最终协议，收购Elanco的水生动物业务，其中包括水生动物药物和疫苗、食品和补充品的创新产品组合。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国动物用药品市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国动物用药品市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国动物用药品市场：产品预估及趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 美国动物用药品市场按产品前景
  • 2018年至2030年市场规模、预测与趋势分析

第五章美国动物用药品市场：动物种类估算及趋势分析

  • 2023 年和 2030 年动物类型市场占有率
  • 细分仪表板
  • 按动物类型分類的美国动物用药品市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第六章美国动物用药品市场：给药途径预估及趋势分析

  • 2023 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 按给药途径分類的美国动物用药品市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第七章美国动物用药品市场：通路估算及趋势分析

  • 2023 年及 2030 年分销通路市场占有率
  • 细分仪表板
  • 美国动物用药品市场分布前景
  • 2018年至2030年市场规模、预测与趋势分析

第八章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market heat map analysis, 2023
  • 公司简介
    • Zoetis Services LLC
    • Boehringer Ingelheim International GmbH
    • Merck &Co., Inc.
    • Elanco
    • Ceva
    • Phibro Animal Health Corporation
    • Bimeda Corporate
    • IDEXX
    • Vetbiologics
    • Neogen Corporation
    • ADM
    • Kindred Biosciences, Inc.
    • Cargill, Incorporated
Product Code: GVR-4-68040-197-8

U.S. Veterinary Market Growth & Trends:

The U.S. veterinary medicine market size is anticipated to reach USD 21.80 billion by 2030 and is projected to grow at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence rates of zoonotic diseases, increased livestock population, growing focus on preventive care, advancements in pet medicine and increasing pet ownership are the major factors contributing to the market growth. According to the March 2023 report released by the American Pet Products Association (APPA), dogs are the most popular pets in the U.S., with 65.1 million households owning a dog. Cats come in second with 46.5 million households, followed by freshwater fish with 11.1 million households.

The livestock population has grown significantly, leading to an increase in zoonotic diseases and chronic diseases. This has led to a growing emphasis on preventive healthcare measures to maintain the health and productivity of animals. Moreover, advancements in technology have revolutionized veterinary medicine by enhancing diagnostic capabilities, treatment options, and medical devices, thereby improving the quality of animal care.

U.S. Veterinary Medicine Market Report Highlights:

  • Based on products, the pharmaceuticals segment led the market with the largest revenue share of 67.6% in 2023, owing to growing investments in research and development and advancements in the field of medicine
  • Based on the animal type, the production animals segment held the market with largest revenue share of 58.5% in 2023, due to an increasing demand for animal protein due to population growth and globalization of livestock production. Companion animals in animal type segment are anticipated to witness fastest CAGR over the forecast period
  • Based on route of administration, the injectable segment dominated the market in 2023 and oral segment is anticipated to witness a significant growth in CAGR over the forecast period, owing to an increasing pet ownership and focus on preventive healthcare
  • Based on distribution channel, the veterinary hospitals & clinics segment held the majority of the market share in 2023 and e-commerce segment is expected to grow at the fastest CAGR over forecast period
  • In February 2024, Merck & Co., Inc. announced the signing of a definitive agreement to acquire the aqua business of Elanco, which includes an innovative portfolio of medications and vaccines, food, and supplements for aquatic animals

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Animal type
    • 1.2.3. Route of administration
    • 1.2.4. Distribution channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Animal type outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing pet ownership
      • 3.2.1.2. Rising incidences of zoonotic diseases
      • 3.2.1.3. Advancements in pet medicine
      • 3.2.1.4. Growing focus on preventive care.
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations & approvals
      • 3.2.2.2. Rising costs associated with animal healthcare
  • 3.3. U.S. Veterinary Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Legal landscape
      • 3.3.2.6. Environmental landscape

Chapter 4. U.S. Veterinary Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Veterinary Medicine Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Biologics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1. Vaccines
      • 4.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.1. Modified/ Attenuated live
      • 4.4.1.1.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.2. Inactivated (Killed)
      • 4.4.1.1.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.3. Other vaccines
      • 4.4.1.1.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.2. Other biologics
      • 4.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Pharmaceuticals
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.1. Parasiticides
      • 4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.2. Anti-infectives
      • 4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.3. Anti-inflammatory
      • 4.4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.4. Analgesics
      • 4.4.2.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.5. Others
    • 4.4.3. Medicated feed additives
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Veterinary Medicine Market: Animal Type Estimates & Trend Analysis

  • 5.1. Animal Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Veterinary Medicine Market by Animal Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Production animals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.1. Poultry
      • 5.4.1.1.1.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.2. Pigs
      • 5.4.1.1.2.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.3. Cattle
      • 5.4.1.1.3.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.4. Sheep & goats
      • 5.4.1.1.4.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.5. Others
      • 5.4.1.1.5.1. Market estimated and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Companion animals
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.1. Dogs
      • 5.4.2.1.1.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.2. Cats
      • 5.4.2.1.2.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.3. Horses
      • 5.4.2.1.3.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.4. Others
      • 5.4.2.1.4.1. Market estimated and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Veterinary Medicine Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Veterinary Medicine Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oral
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Injectable
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.3. Topical
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.4. Other routes
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. U.S. Veterinary Medicine Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Veterinary Medicine Market by Distribution Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Veterinary hospitals & clinics
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. E-commerce
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.3. Offline retail stores
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.4. Others
      • 7.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Zoetis Services LLC
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boehringer Ingelheim International GmbH
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Elanco
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Ceva
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Phibro Animal Health Corporation
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Bimeda Corporate
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. IDEXX
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Vetbiologics
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Neogen Corporation
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. ADM
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Kindred Biosciences, Inc.
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Cargill, Incorporated
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product benchmarking
      • 8.4.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. veterinary medicine market, by product, 2018 - 2030 (USD Million)
  • Table 3 U.S. veterinary medicine market, by animal type, 2018 - 2030 (USD Million)
  • Table 4 U.S. veterinary medicine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 U.S. veterinary medicine market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Veterinary medicine market: market outlook
  • Fig. 10 U.S. Veterinary medicine competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Veterinary medicine market driver impact
  • Fig. 16 U.S. Veterinary medicine market restraint impact
  • Fig. 17 U.S. Veterinary medicine market strategic initiatives analysis
  • Fig. 18 U.S. Veterinary medicine market: Product outlook and key takeaways
  • Fig. 19 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Modified/ Attenuated live market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Inactivated (Killed) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Other vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Other biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Parasiticides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Anti-infectives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Anti-inflammatory market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Analgesics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Medicated feed additives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Veterinary medicine market: Animal type movement analysis
  • Fig. 33 U.S. Veterinary medicine market: Animal type outlook and key takeaways
  • Fig. 34 Production animals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Poultry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Pigs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Cattle market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Sheep & goats market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Companion animals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Dogs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Cats market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Horses market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Veterinary medicine Market: Product movement Analysis
  • Fig. 46 U.S. Veterinary medicine market: Route of administration movement analysis
  • Fig. 47 U.S. Veterinary medicine market: Route of administration outlook and key takeaways
  • Fig. 48 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Other routes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Veterinary medicine market: Distribution channel movement analysis
  • Fig. 53 U.S. Veterinary medicine market: Distribution channel outlook and key takeaways
  • Fig. 54 U.S. Veterinary hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 E-commerce market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Offline retail stores market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Market share of key market players- U.S. Veterinary medicine market